-
First-line treatment of esophageal squamous cell carcinoma!
Time of Update: 2022-08-12
In a planned interim analysis, the dual primary endpoints of progression-free survival (PFS) and overall survival (OS) were met as assessed by the Independent Data Monitoring Committee (IDMC) On May 18, Henlius announced that its innovative PD-1 inhibitor slulimumab combined with chemotherapy in the first-line treatment of patients with locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) was launched in the Phase 3 clinical study ASTRUM-007.
-
The license transaction will continue to be hot Fosun Pharma acquires the rights of an oncology drug in China
Time of Update: 2022-08-12
According to statistics, in 2021, there will be a total of 128 license in transactions in China's pharmaceutical industry, most of which are introduced through the rights and interests of innovative drug projects .
-
NMPA revises the instructions for Changyanning preparations, Yinzhihuang oral preparations, etc.
Time of Update: 2022-08-12
The [Adverse Reactions], [Contraindications] and [Precautions] items of the drug insert were revised uniformly On May 24, the State Food and Drug Administration issued an announcement stating that, according to the results of the adverse drug reaction assessment, in order to further ensure the safety of public medication, the State Drug Administration decided to impose restrictions on Changyanning preparations, Yinzhihuang oral preparations and ginkgolide injections.
-
Novartis "Eltrombopag" approved for new indications in China
Time of Update: 2022-08-12
On May 20, Novartis announced that the new indication of Eltrombopag ethanolamine tablets was approved in China for the treatment of chronic immune (idiopathic) children aged 6-11 who have not responded well to glucocorticoids and immunoglobulins.
-
The pharmaceutical and biological sector has attracted much attention from insurance funds, and these stocks have been investigated together
Time of Update: 2022-08-12
During the survey, the agency mainly focused on the income brought by the new infrastructure to the company, the progress of overseas business, how to deal with the changes brought about by the accelerated promotion of the DRG/DIP payment system, the company's strategy for dealing with the high-quality development of public hospitals, and how to deal with international expansion challenges , etc.
-
35 kinds of medicinal materials were selected into the catalogue of authentic medicinal materials in Hunan Province!
Time of Update: 2022-08-12
Recently, the Hunan Provincial Administration of Traditional Chinese Medicine issued a public announcement on the catalogue of authentic medicinal materials in Hunan Province (the first batch) .
-
New Era Pharmaceutical's Esomeprazole Sodium for Injection has entered the stage of administrative approval
Time of Update: 2022-08-12
Source: State Food and Drug Administration official websiteEsomeprazole is a proton pump inhibitor of gastric parietal cells, which can specifically inhibit H+, K+-ATPases on the secretory microtubules formed by the top membrane of parietal cells and tubular vesicles in the cytoplasm, thereby effectively inhibiting gastric acid.
-
The R&D personnel of 4 traditional Chinese medicine companies account for more than 20%, and Shanghai Kaibao accounts for more than 30%
Time of Update: 2022-08-12
Only four traditional Chinese medicine companies account for more than 20% of the research and development personnel, namely Shanghai Kaibao, Zhongsheng Pharmaceutical, Tailong Pharmaceutical and Huashen Technology .
-
In-depth analysis of the procurement volume of the two major alliances, centralized procurement forces the rational admission of traditional Chinese medicine imitation
Time of Update: 2022-08-12
New entrants cut prices for the market It can be seen from the centralized procurement rules of the Hubei Regional Alliance and the Guangdong Regional Alliance for the centralized procurement of Chinese patent medicines that if the generic varieties of traditional Chinese medicines want to compete for the market, it is difficult to obtain the procurement volume of medical institutions at the beginning .
-
The trillion-dollar health industry market is about to emerge, how should pharmaceutical companies stand out?
Time of Update: 2022-08-12
Therefore, in recent years, the state has also issued a series of favorable policies to further promote the development of the big health industry With the gradual improvement of living standards, people's demand for health services is very urgent.
-
Unannounced inspections in 2021 found suspected illegal use of medical insurance funds exceeding 500 million yuan
Time of Update: 2022-08-12
. The announcement stated that during the inspection, the national unannounced inspection team found that the designated medical institutions had medical insurance management problems and repeated charges, excessive charges, disaggregated item charges, excessive diagnosis and treatment in violation of diagnosis and treatment standards , excessive inspection, exceeding medical insurance payment limits for medication, and alternate diagnosis and treatment.
-
The National Development and Reform Commission and others jointly announced the List of the Third Batch of National Regional Medical Center Construction Projects
Time of Update: 2022-08-12
Xinjiang Hospital, Beijing Children's Hospital Affiliated to Capital Medical University According to the decisions and arrangements of the Party Central Committee and the State Council, in October 2019, the National Development and Reform Commission, the National Health Commission, the Bureau of Traditional Chinese Medicine, and the Secretariat of the Leading Group for Medical Reform of the State Council (hereinafter referred to as the "four departments") launched the pilot work of national regional medical centers.
-
A number of domestic class 1 new drugs, with annual sales exceeding 3 billion!
Time of Update: 2022-08-12
Specifically, Chia Tai Tianqing Pharmaceutical's Anlotinib Hydrochloride Capsules was approved for marketing in May 2018, and was included in the National Medical Insurance Category B catalog through negotiation in the same year, and 5 indications have been achieved so far .
-
Chinese medicine ushered in favorable policies again, which types of enterprises will benefit?
Time of Update: 2022-08-12
It is recommended to pay attention to the sound sales system, and the prescription Chinese patent medicine companies and the companies with differentiated advantages in the subdivision field that have the ability to research and develop innovative traditional Chinese medicines from theoretical research, new drug discovery and transformation, clinical trials, and evidence accumulation of evidence-based medicine.
-
official document!
Time of Update: 2022-08-12
The total revenue of medicines and consumables is "targeted" Cyberlane has noticed that in the new version of the "Public Hospital Party Committee Secretary and Dean's Target Annual Salary Assessment Plan", there are detailed constraints on the procurement of consumables and payment .
-
Head to head!
Time of Update: 2022-08-12
FinishingLinanThe price of Lilly’s recently approved diabetes drug Mounjaro (tirzepatide) was exposed, with a monthly treatment price of about $974 (4 sticks), which is lower than Novo Nordisk’s weight loss drug Wegovy (semaglutide, GLP-1 receptor body agonist, 2.
-
A pharmaceutical company announced a price increase plan, two types of drugs will increase the price
Time of Update: 2022-08-12
Recently, China Resources Sanjiu mentioned in its investor relations activity record sheet that it will raise the price of some OTC products .
Recently, China Resources Sanjiu mentioned in its investor relations activity record sheet that it will raise the price of some OTC products .
-
The ophthalmology market is growing rapidly, and a large number of companies are accelerating their entry
Time of Update: 2022-08-12
Regarding the frequent increase in the ophthalmology market, Yuyue Medical has publicly stated that ophthalmic medical device products and contact lens-related products have become its strategically planned incubation business.
-
Zhejiang increases the reimbursement ratio of medical insurance for infants and young children aged 0-6 and includes IVF and other medical insurance in due course
Time of Update: 2022-08-12
Recently, Zhejiang Province issued the "Notice of Zhejiang Provincial Medical Security Bureau on Supporting "Zheyou Shanyu" to promote prenatal and postnatal care work (draft for comments) . The noti
-
Pfizer and Eli Lilly Announce Positive Phase 3 Clinical Results for Ulcerative Colitis
Time of Update: 2022-08-12
Retrieved May 24, 2022, from https:// -of-patients-with-ulcerative-colitis-treated-with-mirikizumab-achieved-clinical-remission-at-one-year-in-lillys-pivotal-phase-3-study-301552268.
Retrieved May 24, 2022, from https:// -of-patients-with-ulcerative-colitis-treated-with-mirikizumab-achieved-clinical-remission-at-one-year-in-lillys-pivotal-phase-3-study-301552268.
Retrieved May 24, 2022, from https:// -of-patients-with-ulcerative-colitis-treated-with-mirikizumab-achieved-clinical-remission-at-one-year-in-lillys-pivotal-phase-3-study-301552268.
Retrieved May 24, 2022, from https:// -of-patients-with-ulcerative-colitis-treated-with-mirikizumab-achieved-clinical-remission-at-one-year-in-lillys-pivotal-phase-3-study-301552268.
Retrieved May 24, 2022, from https:// -of-patients-with-ulcerative-colitis-treated-with-mirikizumab-achieved-clinical-remission-at-one-year-in-lillys-pivotal-phase-3-study-301552268.
Retrieved May 24, 2022, from https:// -of-patients-with-ulcerative-colitis-treated-with-mirikizumab-achieved-clinical-remission-at-one-year-in-lillys-pivotal-phase-3-study-301552268.
